ALKBH5 silencing or the use of ALKBH5 inhibitors in tumours improves immunotherapy efficacy [125], implying that ALKBH5 is a promising target for immunotherapy in melanoma, CRC, and perhaps other cancers. This evidence concerns the gene ALKBH5 and neoplasm.